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ABSTRACT
Objectives: Recurrent pregnancy loss (RPL) is a serious problem in the reproductive age women. We aimed to study the role 
of anticoagulant therapy on pregnancy complications and perinatal outcomes in pregnant patients with histories of RPL.
Material and methods: One hundred fifty-three pregnants, with RPL history and thrombophilia positivity, were grouped 
into two as 89 treated with anticoagulant therapy and 64 non-treated. Treated and untreated groups were compared for 
pregnancy complications, delivery weeks, abortion rates, fetal birth weights, APGAR scores, live birth rates, and newborn 
intensive care admission rates.
Results: Of the total 153 pregnant patients (63%) 97 developed pregnancy complications; 55 (56.7%) were in the untreated 
group and 42 (43.3%) were in the treated group, which was statistically significant (p = 0.003). The differences in pregnancy 
complications were produced by differences in the numbers of IUFDs and anembryonic fetuses among the groups. The 
average neonatal birth weights of infants whose mothers had taken LMWH + ASA were significantly higher (p=0.011). The 
prematurely delivered infants were admitted to the neonatal intensive care unit (NICU), and the NICU requirements were 
not statistically different between the groups (p = 0.446). However, live birth rates were significantly higher in the treated 
group than in the untreated group (p = 0.001).
Conclusions: Anticoagulant therapy improves pregnancy complications and live birth rates in patients with RPL and 
hereditary thrombophilia.
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INTRODUCTION
Recurrent pregnancy loss (RPL), traditionally defined as 
three or more miscarriages before 20 weeks of gestation, 
continues to be an important problem among women of 
reproductive age [1], affecting approximately 1–2% of all 
pregnancies [1]. The American College of Obstetricians and 
Gynecologists describes RPL as two or more sequential mis-
carriages, a definition which increases the incidence rate to 
5% [2]. While the causes of approximately half of RPL cases 
are undetermined, the remaining half are considered to 
be due to genetic and anatomic abnormalities, endocrine 
diseases, thrombophilia, and immunologic disorders. The 
association between inherited thrombophilia and RPL was 
first reported by Sanson et al., in 1996 [3]. Various thrombo-
philic polymorphisms have been associated with RPL. The 
type of thrombophilia and the mode of fetal loss play a role 
in this relationship [4].
Different authors have confirmed the important role of 
thrombophilia in RPL [5, 6]. Thrombophilia also causes early 
intrauterine fetal demise (IUFD), pre-eclampsia, and abruptio 
placentae. The main cause of obstetric complications is in-
adequate placental perfusion due to hemostatic imbalance 
[7]. Factor V Leiden (FVL), prothrombin (PT G202I0A), methyl-
enetetrahydrofolate reductase C677T, and A1298 mutations 
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(MTHFR), as well as protein C, protein S, and antithrombin 
III deficiencies are the most common causes of hereditary 
thrombophilia. Acquired cases of thrombophilia are due to 
the presence of antiphospholipid antibodies, such as lupus 
anticoagulant and anticardiolipin antibody [8].
Successful pregnancy outcomes depend on sufficient 
utero-placental circulation because hemostatic disorders 
may cause obstruction in the placental vessels, resulting in 
pregnancy complications, in particular miscarriage [7]. For 
this reason, antithrombotic prophylaxis has been used to 
prevent pregnancy complications. According to one me-
ta-analysis, data on maternal hereditary thrombophilia and 
early fetal loss are limited [9]. However, thromboprophylaxis 
is suggested to be helpful in antiphospholipid syndrome 
cases [10]. Due to considerable variability in research meth-
odology, low number of study patients and placebo group 
participants, as well as differences in the choices and dura-
tion of medication, the results of these studies are not sat-
isfactory. Although, according to the current literature, the 
effectiveness of anticoagulant prophylaxis is controversial, 
it has been widely used in pregnant patients with previous 
poor obstetric history to prevent pregnancy complications 
and to improve live birth rates.
For the above-stated reasons, the present study focused 
on the role of anticoagulant therapy in pregnant patients 
with history of RPL. In addition, we aimed to detect the ef-
fect of anticoagulant therapy on pregnancy complications 
and on perinatal outcomes.
MATERIAL AND METHODS
A retrospective review of the medical records of preg-
nant patients, who were admitted to the Bulent Ecevit Uni-
versity Antenatal Care outpatient clinic between 2012 and 
2014, was conducted. Local Ethics Committee approved of 
the study. Pregnant patients with history of two or more ear-
ly pregnancy losses were studied. Women with chronic dis-
eases, autoimmune disorders, infectious diseases, abnormal 
fetal or parental karyotypes, uterine anomalies, endocrine 
disorders, positive antiphospholipid antibodies, or having 
a known cause of RPL other than hereditary thrombophilia 
were excluded from the study. Of the 153 patients who 
met the inclusion criteria, the most commonly screened 
inherited thrombophilia mutations (FVL, PT G202I0A, and 
MTHFR C677T/A1298 mutations) were noted. Our study 
group included patients with history of RPL, at least one 
type of mutation of the most commonly screened thrombo-
philia, and no history of anticoagulant therapy during their 
previous pregnancies. The selection of the study group is 
illustrated in Table 1.
Patient records were reviewed for age, gravidity, parity, 
previous abortions, and live births. Inherited thrombophilia 
patterns were recorded. Patients were then divided into two 
groups according to whether they had or had not received 
anticoagulant therapy during their last pregnancy. Patients 
who had received anticoagulant therapy took low-molecu-
lar-weight heparin (LMWH, 100 IU/kg) + acetylsalicylic acid 
(ASA), 80 mg/day.
Treated and untreated groups were compared for preg-
nancy complications (IUFD, anembryonic pregnancy, ges-
tational diabetes, intrauterine growth retardation [IUGR], 
pre-eclampsia, placental abruption, and placenta previa), 
gestational age at delivery (weeks), and modes of delivery 
with respect to the last pregnancy, cesarean indications, 
abortion rates, fetal birth weights, APGAR scores, live birth 
rates, and newborn intensive care admission rates.
Hereditary thrombophilia genetic tests for Factor V Lei-
den, PT G20210A, and MTHFR C677T/A1298C gene poly-
morphisms were analyzed by polymerase chain reaction. 
Patients with more than one mutation were categorized 
as combined thrombophilia in determining thrombophilia 
patterns.
Statistical analysis
Statistical analyses were performed with SPSS 19.0 soft-
ware (SPSS Inc., Chicago, IL). Distribution of data was deter-
mined by the Shapiro-Wilk test. Continuous variables were 
expressed as mean ± standard deviation or median (mini-
mum–maximum), and categorical variables as frequency 
and percent. Continuous variables were compared with 
the independent sample t-test or Mann-Whitney U test, 
and categorical variables were compared using Pearson’s 
chi-square test or the Fisher exact chi-square test. The 
p-value of < 0.05 was considered as statistically significant 
for all tests.
RESULTS
One hundred and fifty-three patients with at least one 
type of hereditary thrombophilia and history of two or more 
early pregnancy losses were included in the study. Of the 
153 patients, 96 (62.7%) had no living children, 50 (32.7%) had 
1 living child, and 7 (4.6%) had 2 living children. Sixty-four pa-
tients had not received any anticoagulant treatment, whereas 
eighty-nine had received LMWH + ASA during their last preg-
nancy. Median age of the treated and the untreated groups 
was 31 (20–41) and 31 (20–40) years, respectively, and the 
difference was not statistically significant (p = 0.603). Gravid-
ity, parity, abortion, and previous live birth rates were not 
statistically different between the groups (Table 1).
In the untreated group, 48 women (75%) had MTHFR 
mutations (14 homozygous and 34 heterozygous); 4 (6.3%) 
had PT G202I0A mutations (1 homozygous and 3 heterozy-
gous); and only 1 patient had an FVL heterozygous mutation. 
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A total of 11 subjects (17.2%) were combined thrombophilia 
carriers (Table 1). In the treated group, 52 (58.4%) had MTHFR 
mutations (18 homozygous and 34 heterozygous), 4 (4.5%) 
had heterozygous PT G202I0A mutations, and 3 (3.3%) pa-
tients had FVL mutations (1 homozygous and 2 heterozy-
gous). A total of 30 (17.2%) treated patients were combined 
thrombophilia carriers (Table 2).
Patient records were reviewed for maternal complica-
tions during the latest pregnancy (Table 3). Of the total 
153 pregnant patients, 97 (63%) developed pregnancy com-
plications: 55 (56.7%) in the untreated and 42 (43.3%) in the 
treated group. Statistically significant differences between 
the two groups were observed (p = 0.003). Differences in 
pregnancy complication rates resulted from the differences 
in the numbers of IUFDs and anembryonic fetuses among 
the groups. Intrauterine exitus was observed in 31 (56.4%) 
of the untreated patients, whereas 14 (33.3%) of the treated 
patients had IUFDs. Also, 17 (30.9%) pregnancies from the 
Table 1. Demographic properties of the patients
LMWH + ASA treated group  (n = 89) Untreated group (n = 64) P value
Age 31 (20–41) 31 (20–40) 0.603
Gravida 4 (2–9) 3 (2–6) 0.036
Parity 2 (0–3) 2 (0–3) 0.441
Abortions 2 (2–8) 2 (2–4) 0.055
Live births 0 (0–2) 0 (0–2) 0.370
The datas were given as median (min–max). p < 0.05 was accepted as significant
Table 2. Mutation status of the groups 
Mutation LMWH + ASA treatedN (%)
Untreated
N (%)
MTHFR
Homozygous
Heterozygous
 
18 (20.2%)
34 (22.2%)
 
14 (21.9%)
34 (53.1%)
PT
Homozygous
Heterozygous
 
0 (0%)
4 (4.5%)
 
0 (1.6%)
3 (4.7%)
FVL
Homozygous
Heterozygous
 
0 (1.1%)
2 (2.2%)
 
0 (0%)
1 (1.6%)
Combined mutation 30 (33.7%) 11 (33.7%)
Total 89 (100%) 64 (100%)
Results are given as number (%). Percentiles are given within the group. Combined mutation is accepted as one or more type of hereditary thrombophilia positivity
Table 3. Pregnancy outcomes of the groups with RPL and thrombophilia 
Obstetric complications LMWH + ASA treatedN (%)
Untreated
N (%)
Intrauterine fetal demise (IUFD) 14 (33.3%) 31 (56.4%)
Anembryonic pregnancy 6 (14.3%) 17 (30.9%)
Gestational diabetes (GDM) 9 (21.4%) 2 (3.6%)
Intrauterine growth retardation (IUGR) 3 (7.1%) 2 (3.6%)
Preeclampsia 7 (16.7%) 2 (3.6%)
Abruptio placenta 1 (2.4%) 0 (0%)
Placenta previa 2 (4.8%) 1 (1.8%)
Total 42 (100%) 55 (100%)
Results are given as number (%). Percentiles are given within the group. The total number of complication was statistically higher in untreated group (p = 0.003).  
The difference in pregnancy complications was produced by the differences in the numbers of IUFDs and anembryonic fetuses among groups
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untreated group were terminated due to anembryonic preg-
nancies. Moreover, 6 (14.3%) pregnancies from the treated 
group were terminated for the same reason. When we omit-
ted IUFDs and anembryonic pregnancies, no statistically 
significant differences were noted between the groups with 
regard to other pregnancy complications.
Approximately one-third of pregnancies from the 
untreated group and two-thirds of pregnancies from the 
treated group resulted in live births through cesarean sec-
tion (21.9% and 67.4%, respectively); whereas for vaginal 
delivery the rates were 21.9% and 19.1%, respectively. A total 
of 48 (31.4%) patients had therapeutic curettages due to 
IUFDs or to anembryonic pregnancies, including 36 (56.3%) 
in the untreated and 12 (13.5%) in the treated group. The 
number of patients who underwent therapeutic curettage 
was significantly higher in the untreated group (Table 4). 
Indications for cesarean sections were all due to obstetric 
causes, which are presented in Table 5.
The groups were compared with respect to gestation-
al age at delivery, birth weight, APGAR scores at 1 and 
Table 5. Cesarean indications of the groups
Cesarean indications LMWH + ASA treatedN (%)
Untreated
N (%)
Previous cesarean history 18 (30.5%) 4 (28.6%)
Acute fetal distress 12 (20.3%) 7 (50.0%)
Cefalopelvic disproportion 17 (28.8%) 2 (14.3%)
Abruptio plasenta 2 (3.4%) 0 (0%)
Preeclampsia 4 (6.8) 0 (0%)
Macrosomic fetus 5 (8.5%) 0 (0%)
Placenta previa 1 (1.7%) 1 (7.1%)
Total 59 (100%) 14 (100%)
Results are given as number (%). Percentiles are given within the group
Table 6. Regression model for potentional factors contributing live birth
 
Odds ratio 95,0% CI for EXP(B) P value
Upper Lower Lower Upper
Step 1 Age 0.974 0.487 0.905 1.049
 Abortion history 1.471 0.159 0.859 2.520
 Combined mutation 1.766 0.137 0.834 3.741
 Constant 1.278 0.850   
Table 4. Perinatal outcomes and modes of delivery of groups
LMWH + ASA treated
N (%)
Untreated
N (%)
Delivery week 37 (27–40) 36 (31–40)
Cesarean section 60 (67.4%) 14 (21.9%)
Vaginal delivery (19.1%) 14 (21.9%)
Abortions/currettage 12 (13.5%) 36 (56.3%)
Apgar 1 min 7 (0–9) 8 (0–8)
Apgar 5 min 10 (0–10) 10 (0–10)
Live birth* 68 (80%) 17 (20%)
Neonatal intensive care requirement
Yes
No
 
10 (13.9%)
62 (86.1%)
 
1 (5.6%)
17 (94.4%)
*The ratios are within total number of live birth babies (n = 85). The p value for live birth ratio was significant (p = 0.001)
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5 min, live births, and neonatal intensive care require-
ment rates. Mean neonatal birth weight of infants whose 
mothers had taken LMWH + ASA was significantly higher 
than those whose mothers had not received anticoagulant 
therapy (p = 0.011). Differences between APGAR scores at 
1 and 5 min. were statistically insignificant between the 
groups (p = 0.077 and p = 0.111, respectively). Prematurely 
delivered infants were admitted to the neonatal intensive 
care unit (NICU), and the NICU requirements were not 
statistically different between the groups (p = 0.446). How-
ever, live birth rates were significantly higher in the treated 
group as compared to the untreated group (p = 0.001; 
Table 4).
Regression analyses of live births were performed using 
maternal age, the number of previous abortions, and the 
combined thrombophilia status. Unfortunately, none of the 
investigated risk factors were found to be predictive for risk 
ratio of live births (Table 6).
DISCUSSION
Various authors have reported that poor pregnancy 
outcomes and neonatal risk are increased in pregnant pa-
tients with hereditary thrombophilia [11–13]. For the most 
part, poor obstetric outcomes result from hemostatic dis-
turbances, which cause obstruction in the placental vessels 
[14]. In recent studies, placenta-associated complications 
(IUFD, IUGR, RPL, pre-eclampsia, and placental abruption) 
have been confirmed as the leading causes of maternal/fetal 
morbidity and mortality [15, 16].
It has been demonstrated that a history of RPL also 
constitutes a risk factor for the current pregnancy. Paidas 
et al., stated that the recurrence rate of obstetric complica-
tions without thrombophilia is approximately 23%, with the 
presence of thrombophilia further increasing the risk [17]. 
In another study, pregnant women with poor obstetric his-
tory were shown to have a 52% risk for pre-eclampsia, while 
the risk for IUGR and IUFD was 56% and 48%, respectively 
[18]. In our study, RPL was found in 56 patients (36% in the 
untreated and 13.5% in the treated group).
In accordance with the definition of the American Col-
lege of Obstetricians and Gynecologists [2], the present 
study included pregnant patients whose previous preg-
nancies resulted in two or more miscarriages. Thus, the 
traditional definition of RPL (three or more miscarriages) 
was not considered in this study.
Numerous studies have been conducted in pregnant 
patients with thrombophilia and history of RPL to improve 
maternal and fetal complications and perinatal outcomes. In 
animal models, the improvement of trophoblast invasion 
has been studied with the aid of LMWH in patients with 
history of RPL [19]. Clinical studies have also supported 
this finding. De Carolis et al., demonstrated that the use of 
LMWH in patients with hereditary thrombophilia and poor 
obstetric history resulted in a higher number of live births, 
increased birth weight, and decreased rate of perinatal 
complications [20]. Brenner et al., also found that LMWH 
improved live birth rates [21]. Alguel et al., who detected 
a higher risk in women with history of thromboembolism, 
suggest that LMWH improved the number of favorable 
pregnancy outcomes [22].
With respect to its effectiveness in improving maternal 
and fetal complications, ASA has also been compared with 
LMWH. Giancotti et al., reported that LMWH or LMWH + ASA 
combination therapy is significantly more protective against 
fetal losses than ASA-only treatment [23]. They also rec-
ommend thromboprophylaxis for women with history of 
RPL, without considering the positivity of thrombophilia 
markers. In another study, anticoagulant therapy with 
LMWH + ASA was suggested to provide better obstetric out-
comes in women with thrombophilia and poor obstetric his-
tory [24]. Our study also showed that the use of LMWH + ASA 
increased live birth rates and birth weight. Our results were 
similar to the study of Mak, in which a combination of hepa-
rin and aspirin was found to be superior to aspirin alone in 
enhancing the number of live births in patients with RPL 
and anti-phospholipid antibodies positivity [25].
Our study was not without limitations. First, due to its 
retrospective and not prospective nature, we were able to 
evaluate only one type of anticoagulant treatment mo-
dality used in our clinic. Since performing randomized 
placebo-controlled trials in pregnant patients has been 
a big challenge due to ethical issues, retrospective studies 
generally have been reported. To the best of our knowl-
edge, only two placebo-controlled studies, i.e. the Anti-
coagulant Fetus and the Scottish Pregnancy Intervention, 
have been performed to date [26, 27]. Anticoagulant use in 
patients with RPL independent from thrombophilia posi-
tivity was examined in these studies, which were unable 
to demonstrate a significant difference in live birth rates 
between the study- and control-group patients, since there 
was a contradiction with respect to the design and results 
of the studies.
The other limitation of our study was a relatively small 
sample size. Thus, regression analysis of the potential factors 
(age, number of previous abortions, combined mutation 
status) could not predict the relative risk of live birth.
We reported better perinatal outcomes in patients with 
previous RPL and hereditary thrombophilia in pregnant 
patients treated with anticoagulant therapy. However, rand-
omized controlled trials are needed in order to recommend 
routine administration of anticoagulant therapy to pregnant 
patients with history of RPL. 
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